TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Sponsor: Haihe Biopharma Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 254 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT04390737 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04390737 Rescue Dossier →